Advertisement

Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia

Sarah K. Tasian, David T. Teachey, Yong Li, Feng Shen, Richard C. Harvey, I-Ming Chen, Theresa Ryan, Tiffaney L. Vincent, Cheryl L. Willman, Alexander E. Perl, Stephen P. Hunger, Mignon L. Loh, Martin Carroll and Stephan A. Grupp

Article Information

Citation 
vol. 129 no. 2 177-187
PubMed 

Print ISSN 
Online ISSN 
History 
  • Submitted May 13, 2016
  • Accepted October 17, 2016
  • Published online January 12, 2017.

Article Versions


Contributors 
  • Sarah K. Tasian, 1Division of Oncology, Department of Pediatrics, Center for Childhood Cancer Research, Children’s Hospital of Philadelphia, Philadelphia, PA; 2Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA;
  • David T. Teachey, 1Division of Oncology, Department of Pediatrics, Center for Childhood Cancer Research, Children’s Hospital of Philadelphia, Philadelphia, PA; 2Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA;
  • Yong Li, 1Division of Oncology, Department of Pediatrics, Center for Childhood Cancer Research, Children’s Hospital of Philadelphia, Philadelphia, PA;
  • Feng Shen, 1Division of Oncology, Department of Pediatrics, Center for Childhood Cancer Research, Children’s Hospital of Philadelphia, Philadelphia, PA;
  • Richard C. Harvey, 3Department of Pathology, University of New Mexico, Albuquerque, NM;
  • I-Ming Chen, 3Department of Pathology, University of New Mexico, Albuquerque, NM;
  • Theresa Ryan, 1Division of Oncology, Department of Pediatrics, Center for Childhood Cancer Research, Children’s Hospital of Philadelphia, Philadelphia, PA;
  • Tiffaney L. Vincent, 1Division of Oncology, Department of Pediatrics, Center for Childhood Cancer Research, Children’s Hospital of Philadelphia, Philadelphia, PA;
  • Cheryl L. Willman, 3Department of Pathology, University of New Mexico, Albuquerque, NM;
  • Alexander E. Perl, 2Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; 4Division of Hematology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; and
  • Stephen P. Hunger, 1Division of Oncology, Department of Pediatrics, Center for Childhood Cancer Research, Children’s Hospital of Philadelphia, Philadelphia, PA; 2Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA;
  • Mignon L. Loh, 5Division of Hematology/Oncology, University of California San Francisco Benioff Children’s Hospital, and 6Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA
  • Martin Carroll, 2Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; 4Division of Hematology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; and
  • Stephan A. Grupp, 1Division of Oncology, Department of Pediatrics, Center for Childhood Cancer Research, Children’s Hospital of Philadelphia, Philadelphia, PA; 2Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA;

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output